Factors Associated with Discontinuation of Statin Therapy in Patients with Lymphoma Aged 80 Years and Older: A Retrospective Single-Institute Study.
Factors Associated with Discontinuation of Statin Therapy in Patients with Lymphoma Aged 80 Years and Older: A Retrospective Single-Institute Study.
复制标题
DOI：
10.1007/s40801-022-00314-6
复制
发表时间：
2022-12
影响因子：
2
通讯作者：
Horiuchi, Takahiko
中科院分区：
文献类型：
--
作者：
Yamasaki, Satoshi;Tokunou, Tomotake;Horiuchi, Takahiko
几乎没有证据支持或否定他汀类药物治疗在80岁或以上淋巴瘤患者心血管疾病（CVD）一级预防中的益处。我们对80岁及以上淋巴瘤患者停用他汀类药物治疗失败的综合老年评估（CGA）评分和先前报道的危险因素进行了评估，目的是确定那些需要停用他汀类药物以预防初级心血管疾病的患者。我们的研究队列包括50名年龄在80岁及以上的淋巴瘤患者，于2011年1月至2020年7月在我们研究所接受化疗。我们回顾性分析了CGA（包括老年8、日常生活辅助活动和Charlson合并症指数）与先前报道的他汀类药物停药失败相关因素（定义为停药后重新引入他汀类药物）之间的关系。他汀类药物治疗不超过20年是他汀类药物停药失败的独立预测因子（风险比8.240,95%可信区间1.380-49.10）。他汀治疗≥20年和< 20年的患者停药失败率有显著差异（p = 0.010）。cga相关评分的多变量分析未发现他汀类药物停药失败的显著危险因素。他汀类药物使用20年或以上的80岁及以上淋巴瘤患者可能需要停药。
There is little evidence to support or negate the benefits of statin therapy for primary prevention of cardiovascular disease (CVD) in lymphoma patients aged 80 years or older. We evaluated comprehensive geriatric assessment (CGA) scores and previously reported risk factors for failure of statin therapy discontinuation in lymphoma patients aged 80 years and older with the aim of identifying those in whom discontinuation of statins for primary CVD prevention is indicated. Our study cohort comprised 50 patients aged 80 years and older treated with chemotherapy for lymphoma at our institute from January 2011 to July 2020. We retrospectively analyzed the associations between CGA, including Geriatric 8, instrumental activities of daily living, and Charlson comorbidity index, and previously reported factors associated with failure of statin therapy discontinuation, defined as reintroduction of statins after their discontinuation, in this patient cohort. Twenty years or less of statin therapy was an independent predictor of failure of statin therapy discontinuation (hazard ratio 8.240, 95% confidence interval 1.380–49.10). There were significant differences in the rate of failure of statin discontinuation between patients receiving statins for ≥ 20 years versus < 20 years (p = 0.010). Multivariate analysis of CGA-related scores identified no significant risk factors for failure of statin discontinuation. Discontinuation of statin therapy may be indicated in lymphoma patients aged 80 years and older who have used statins for 20 years or more.